<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146343">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971086</url>
  </required_header>
  <id_info>
    <org_study_id>40.56</org_study_id>
    <nct_id>NCT01971086</nct_id>
  </id_info>
  <brief_title>Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary</brief_title>
  <official_title>Treatment With Rhinospray Plus of Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Hungary: National Institute of Pharmacy</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre, open-label, prospective, uncontrolled, single-arm, non-interventional study
      (NIS) with objective to collect and evaluate data concerning treatment with Rhinospray Plus
      in everyday curative routine treatment of acute rhinitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      open, observational, single-arm, uncontrolled
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The change from baseline in the mean of the 3 single symptom scores (blocked nose, sneezing and running nose) at the closing/final visit.</measure>
    <time_frame>up to day 11</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The mean of the 2 single quality of life improvement scores at the closing/final visit  for daytime activities and quality of sleep</measure>
    <time_frame>up to day 11</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in the single symptoms scores ( blocked nose,  sneezing and running nose) at the closing/final visit</measure>
    <time_frame>up to day 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doctors subjective assessment of overall treatment effectiveness an a 4 points rating scale at the closing/final visit.</measure>
    <time_frame>up to day 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients subjective assessment of overall treatment effectiveness an a 4 points rating scale at the closing/final visit.</measure>
    <time_frame>up to day 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>acute rhinitis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        adults and children at and above 6 years old
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients who (or in case of 6-18 years old whose legal representative) have signed
             the Informed Consent

          2. Male and female ambulatory outpatients being seen in a participating physicians
             office for routine care

          3. Patients with a clinical diagnosis of Rhinitis acuta

          4. Patient having the cognitive and functional abilities for answering the symptom
             specific questions

          5. Patients having expressed the willingness to participate in this observational study

          6. Patients at and above the age of 6

          7. Rhinospray Plus naive patients (patients who have not used Rhinospray Plus before)

        Exclusion criteria:

          1. Uncooperative patients based on physicians judgement

          2. Patients with any conditions making the application of Rhinospray plus
             contraindicated

          3. Patients currently enrolled in any clinical trial which requires a change in
             medication for their respiratory problems

          4. Withdraw of Informed Consent

          5. Pregnancy or breast-feeding as stated in the Summary of Product Characteristic (SmPC)

          6. Patients with clinical diagnosis of allergic rhinitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>40.56.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40.56.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40.56.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40.56.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>October 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tramazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
